The Use of Antiepileptics in the Treatment of Addictive Disorders

Primary Psychiatry

Volumn 10, Issue 10, 2003, Pages 59-63

  Myrick, Hugh ^a,b   Malcolm, Robert ^a   Anton, Raymond ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ALCOHOL; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOMETHIAZOLE; CLONIDINE; DONEPEZIL; GABAPENTIN; GLUTAMIC ACID; LORAZEPAM; NEUROTRANSMITTER; OXAZEPAM; PLACEBO; SERTRALINE; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; VIGABATRIN;

ADDICTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; CLINICAL TRIAL; COCAINE DEPENDENCE; DOSE RESPONSE; DRUG EFFICACY; DRUG USE; HUMAN; OPIATE ADDICTION; RELAPSE; REVIEW; SUBSTANCE ABUSE; WITHDRAWAL SYNDROME;

EID: 1842611611     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Anton RF, Becker HC. Pharmacotherapy and pathophysiology of alcohol withdrawal. In: Kranzler HR, ed. Handbook of Experimental Pharmacology. Berlin, Germany: Springer-Verlag; 1995:114.
2. Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA. 1997;2:144-151.
3. Cooper BR, Viik K, Ferris RM, White HL. Antagonism of the enhanced susceptibility to audiogenic seizures during alcohol withdrawal in the rat by gamma-aminobutyric acid (GABA) and "GABA-mimetic" agents. J Pharmacol Exp Ther 1979;3:396-403.
4. Hoffman PL, Rabe CS, Grant KA, Valverius P, Hudspith M, Tabakoff B. Ethanol and the NMDA receptor. Alcohol. 1990;3:229-231.
5. Littleton J. Neurochemical mechanisms underlying alcohol withdrawal. Alcohol Health Res World. 1998;1:13-24.
6. Griffiths RR, Sannerud VD. Abuse of a dependence on benzodiazepines and other anxiolytic/sedative drugs. In: Herbert Y, Melzer Y, eds. Psychopharmacology the Third Generation of Progress. New York, NY: Raven Press; 2003.
7. The Pharmacologic Basis of Therapeutics. 7th ed. New York, NY: MacMillan Publishing Company; 1985.
8. Malcolm R, Myrick H, Roberts J, Wang W, Anton RF, Ballenger JC. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med. 2002;5:349-355.
9. Brown ME, Anton RF, Malcolm R, Ballenger JC. Alcohol detoxification and withdrawal seizures: clinical support for a kindling hypothesis. Biol Psychiatry. 1988;5:507-514.
10. Bastie Y. Suppression by depakene of epileptic crises caused by withdrawal in alcoholic detoxification. Ann Med Psychol (Paris). 1970;128II:200-204.
11. Bonfiglio C, Falli S, Pacini A. The use of sodium dipropylacetate to prevent and treat alcoholic delirium tremens. Minerva Med. 1977;63:4233-4255.
12. Lambie DG, Johnson RH, Vijayasenan ME, Whiteside EA. Sodium valproate in the treatment of the alcohol withdrawal syndrome. Aust N Z J Psychiatry. 1980;3:213-215.
13. Myrick H, Brady KT, Malcolm R. Divalproex in the treatment of alcohol withdrawal. Am J Drug Alcohol Abuse. 2000;1:155-160.
14. Rosenthal RN, Perkel C, Singh P, Anand O, Miner CR. A pilot open randomized trial of valproate and phenobarbital in the treatment of acute alcohol withdrawal. Am J Addict. 1998;3:189-197.
15. Hillbom ME, Hjelm-Jager M. Should alcohol withdrawal seizures be treated with anti-epileptic drugs? Acta Neurol Scand. 1984;1:39-42.
16. Reoux JP, Saxon AJ, Malte CA, Baer JS, Sloan KL. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res. 2001;9:1324-1329.
17. Sullivan JT, Swift RM, Lewis DC. Benzodiazepine requirements during alcohol withdrawal syndrome: clinical implications of using a standardized withdrawal scale. J Clin Psychopharmacol. 1991;5:291-295.
18. Bjorkqvist SE, Isohanni M, Makela R, Malinen L. Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: a formal multicentre double-blind comparison with placebo. Acta Psychiatr Scand. 1976;5:333-342.
19. Björkqvist SE, Isohanni M, Mäkelä R, et al. Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: a formal multicentre, double-blind comparison with placebo. Acta Psychiatrica Scandinavica. 1976;53:333-342.
20. Sonck T, Malinen L, Hanne J. Carbamazepine in the treatment of acute withdrawal syndrome in alcoholics: methodological aspects. In: Rationality of Drug Development. Excerpta Medica International Congress Series No. 383. Amsterdam: Excerpta Medica. 1976:251.
21. Agricola R, Mazzarino M, Urani R. Treatment of acute alcohol withdrawal syndrome with carbamazepine: a double-blind comparison with tiapride. J Int Med Res. 1982;10:160-165.
22. Malcolm R, Ballenger JC, Sturgis ET, et al. Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry. 1989:146;617-621.
23. Stuppaeck CH, Pycha R, Miller C, Whitworth AB, Oberbauer H, Fleischhacker WW. Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double blind study. Alcohol and Alcohol. 1991;27:153-158.
24. Letterman L, Markowitz JS. Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions. Pharmacotherapy. 1999;5:565-572.
25. Watson WP, Robinson E, Little HJ. The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome. Neuropharmacology. 1997;10:1369-1375.
26. Bailey CP, Molleman A, Little HJ. Comparison of the effects of drugs on hyperexcitability induced in hippocampal slices by withdrawal from chronic ethanol consumption. Br J Pharmacol. 1998;2:215-222.
27. Bonnet U, Banger M, Leweke FM, Maschke M, Kowalski T, Gastpar M. Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiatry. 1999;3:107-109.
28. Stuppaeck CH, Deisenhammer EA, Kurz M, Whitworth AB, Hinterhuber H. The irreversible gamma-aminobutyrate transaminase inhibitor vigabatrin in the treatment of the alcohol withdrawal syndrome. Alcohol Alcohol. 1996;1:109-111.
29. Rustembegovic A, Sofic E, Kroyer G. A pilot study of Topiramate (Topamax) in the treatment of tonic-clonic seizures of alcohol withdrawal syndromes. Med Arh. 2002;4:211-212.
30. Smith DE, Wesson DR. Benzodiazepines and other sedative-hypnotics. In: Galanter M, Kleber H, eds. American Psychiatric Press Textbook of Substance Abuse Treatment. Washington, DC: American Psychiatric Press; 1995.
31. Ries RK, Roy-Byrne PP, Ward NG, Neppe V, Cullison S. Carbamazepine treatment for benzodiazepine withdrawal. Am J Psychiatry. 1989;4:536-537.
32. Schweizer E, Rickels K, Case WG, Greenblatt DJ. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome. Arch Gen Psychiatry. 1991;5:448-452.
33. Klein E, Colin V, Stolk J, Lenox RH. Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. Am J Psychiatry. 1994;12:1760-1766.
34. Apelt S, Emrich HM. Sodium valproate in benzodiazepine withdrawal. Am J Psychiatry. 1990;7:950-951.
35. Roy-Byrne PP, Lewis N, Villacres E, et al. Preliminary evidence of benzodiazepine subsensitivity in panic disorder. Biol Psychiatry. 1989;7:744-748.
36. McElroy SL, Keck PE, Jr., Lawrence JM. Treatment of panic disorder and benzodiazepine withdrawal with valproate. J Neuropsychiatry Clin Neurosci. 1991;2:232-233.
37. Rickels K, Schweizer E, Garcia EF, Case G, DeMartinis N, Greenblatt D. Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome. Psychopharmacology (Berl). 1999;1:1-5.
38. Krenz SL, Zimmerman G, Pin M, et al. Topiramate in multidrug withdrawal - comparison with clonidine. Eur Psychiatry. 2002;17(suppl 1):213-214.
39. Zullino DF, Cottier AC, Besson J. Topiramate in opiate withdrawal. Prog Neuropsychopharmacol Biol Psychiatry. 2002;6:1221-1223.
40. Satel SL, Kosten TR, Schuckit MA, Fischman MW. Should protracted withdrawal from drugs be included in DSM-IV? Am J Psychiatry. 1993;5:695-704.
41. Moeller FG, Barratt ES, Dougherty DM, Schmitz JM, Swann AC. Psychiatric aspects of impulsivity. Am J Psychiatry. 2001;11:1783-1793.
42. Keck PE, Jr, McElroy SL, Friedman LM. Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. J Clin Psychopharmacol. 1992;1:(suppl):36S-41S.
43. Lindenmayer JP, Kotsaftis A. Use of sodium valproate in violent and aggressive behaviors: a critical review. J Clin Psychiatry. 2000;2:123-128.
44. Henderson MJ, Galen LW, DeLuca JW. Temperament style and substance abuse characteristics. Subst Abuse. 1998;2:61-70.
45. Anton RF. Pharmacologic approaches to the management of alcoholism. J Clin Psychiatry. 2001;62(suppl 20):11-17.
46. Mueller TI, Stout RL, Rudden S, et al. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res. 1997;1:86-92.
47. Brady KT, Myrick H, Henderson S, Coffey SF. The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depend. 2002;3:323-330.
48. Longo LP, Campbell T, Hubatch S. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. J Addict Dis. 2002;2:55-64.
49. Karam-Hage M, Brower KJ. Gabapentin treatment for insomnia associated with alcohol dependence. Am J Psychiatry. 2000;1:151.
50. Rubio G, Ponce G, Jimenez-Arriero MA, Palomo T, Ferre F. Effectiveness of topiramate in control of alcohol craving [abstract]. Presented at: the European Congress of Neuropsychopharmacology Regional Meeting; April 19, 2002; Bucharest, Romania.
51. Komanduri R. Two cases of alcohol craving curbed by topiramate. J Clin Psychiatry. 2003;5:612.
52. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361:1677-1685.
53. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
54. Gibbs JW, III, Sombati S, DeLorenzo RJ, Coulter DA. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia. 2000;41(suppl 1):S10-S16.
55. Petroff OA, Hyder F, Rothman DL, Mattson RH. Topiramate rapidly raises brain GABA in epilepsy patients. Epilepsia. 2001;4:543-548.
56. Lima AR, Lima MS, Soares BG, Farrell M. Carbamazepine for cocaine dependence. Cochrane Database Syst Rev. 2001;4:CD002023.
57. Brady KT, Sonne SC, Malcolm RJ, et al. Carbamazepine in the treatment of cocaine dependence: subtyping by affective disorder. Exp Clin Psychopharmacol. 2002;3:276-285.
58. Halikas JA, Center BA, Pearson VL, Carlson GA, Crea F. A pilot, open clinical study of depakote in the treatment of cocaine abuse. Hum Psychopharmacol. 2001;3:257-264.
59. Myrick H, Henderson S, Brady KT, Malcolm R, Measom M. Divalproex loading in the treatment of cocaine dependence. J Psychoactive Drugs. 2001;3:283-287.
60. Myrick H, Henderson S, Brady KT, Malcolm R. Gabapentin in the treatment of cocaine dependence: a case series. J Clin Psychiatry. 2001;1:19-23.
61. Winhusen T, Somoza E. The HPA axis in cocaine use: implications for pharmacotherapy. J Addict Dis. 2001;3:105-119.